Control Bionics Limited (CBL.AX)
ASX · AUD · Healthcare · Medical Devices
A$0.05 (-5.66%) as of
Key statistics
- Market cap
- 27.21M
- Forward P/E
- -2.50
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0320 – 0.0950
- Beta
- 0.06
- Revenue (TTM)
- 4.77M
- Profit margin
- -152.42%
- Volume
- 1.84M
About Control Bionics Limited
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; and switch systems comprising proximity, press, and finger switches. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Cremorne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.